Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Euro-Med Laboratories Philippines EV-to-EBIT?
Euro-Med Laboratories PhilippinesPHS:EURO 81 EV-to-EBIT is 7.10 as of Aug. 12, 2026, which is 42% below its 10-year median of 12.28. GuruFocus rates PHS:EURO with a GF Score™ of 81/100 and a GF Value™ of ₱1.04 (Fairly Valued). The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Euro-Med Laboratories Philippines ranks better than 82.38% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Euro-Med Laboratories Philippines's Enterprise Value for the quarter that ended in Mar. 2026 was ₱6,561 Mil.
Euro-Med Laboratories Philippines's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₱947 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euro-Med Laboratories Philippines EV-to-EBIT Related Terms
Euro-Med Laboratories Philippines EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHS:EURO vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's EV-to-EBIT falls into.
Euro-Med Laboratories Philippines's current Enterprise Value is ₱6,726 Mil.
Euro-Med Laboratories Philippines's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₱947 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euro-Med Laboratories Philippines (PHS:EURO) has a EV-to-EBIT of 7.10 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Euro-Med Laboratories Philippines and its competitors. This is 42% below median its historical median of 12.28. Over the past decade, Euro-Med Laboratories Philippines' EV-to-EBIT has ranged from 6.84 to 44.73. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #120 out of 681 companies in the Drug Manufacturers industry, placing it in the top 17.6%.
Is Euro-Med Laboratories Philippines' EV-to-EBIT too high?
Euro-Med Laboratories Philippines' current EV-to-EBIT of 7.10 is 42% below median its 10-year median of 12.28. Over the past 10 years, this metric has ranged from a low of 6.84 to a high of 44.73. The Drug Manufacturers industry median EV-to-EBIT is 15.99. Euro-Med Laboratories Philippines' value of 7.10 is 55.6% below this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #120 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #120 out of 681 companies for EV-to-EBIT. This places Euro-Med Laboratories Philippines in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.99. Euro-Med Laboratories Philippines' value of 7.10 is 55.6% below this benchmark. Historically, Euro-Med Laboratories Philippines' own EV-to-EBIT has ranged from 6.84 to 44.73 over the past decade. While the company's 10-year median is 12.28 vs. the industry median of 15.99, Euro-Med Laboratories Philippines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current EV-to-EBIT of 7.10 is 55.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current EV-to-EBIT is 7.10, which is 42% below median its own 10-year median of 12.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.04, compared to a current price of ₱1.04 — trading right at its estimated fair value. The current EV-to-EBIT is 7.10, which is 42% below median its 10-year median of 12.28 and 55.6% below the Drug Manufacturers industry median of 15.99. Euro-Med Laboratories Philippines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current EV-to-EBIT is 7.10 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be undervalued.
The current stock price of ₱1.04 is trading 0% below its estimated GF Value™ of ₱1.04.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
EV-to-EBIT: 7.10 (42% below median its 10-year median of 12.28)
GF Value™: ₱1.04 vs. price of ₱1.04 (0% below fair value)
Industry Position: 55.6% below the Drug Manufacturers median (#120 of 681)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
81GF Score
Get the complete analysis for PHS:EURO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
